Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

James, Stefan, Erlinge, David, Storey, Robert F., McGuire, Darren K., de Belder, Mark, Eriksson, Niclas, Andersen, Kasper, Austin, David, Arefalk, Gabriel, Carrick, David, Hofmann, Robin, Hoole, Stephen P., Jones, Daniel A., Lee, Kelvin, Tygesen, Hans, Johansson, Peter A., Langkilde, Anna Maria, Ridderstråle, Wilhelm, Parvaresh Rizi, Ehsan, Deanfield, John, Oldgren, Jonas·2024·NEJM Evidence

Abstract

BACKGROUND: In patients with acute myocardial infarction (MI), therapies that could further reduce the risk of adverse cardiovascular and metabolic outcomes are needed. METHODS: In this international registry-based, randomized, double-blind trial, patients without prior diabetes or chronic heart failure, presenting with acute MI and impaired left ventricular systolic function, were randomly assigned 10 mg of dapagliflozin or placebo, given once daily. The primary outcome was the hierarchical composite of death, hospitalization for heart failure, nonfatal MI, atrial fibrillation/flutter, type 2 diabetes mellitus, New York Heart Association Functional Classification at the last visit, and body weight decrease of 5% or greater at the last visit using the win ratio analysis method. The key secondary outcome was the same hierarchical composite excluding the body weight component. RESULTS: We enrolled 4017 patients of whom 2019 were assigned to dapagliflozin and 1998 to placebo. The analysis of the primary hierarchical composite outcome resulted in significantly more wins for dapagliflozin than for placebo (win ratio, 1.34; 95% confidence interval [CI], 1.20 to 1.50; P<0.001). The win ratio outcome, which was adopted in a change of analysis during trial performance because of low event accrual, was mainly driven by the added cardiometabolic outcomes. The composite of time to cardiovascular death/hospitalization for heart failure occurred in 50/2019 (2.5%) patients assigned to dapagliflozin and 52/1998 (2.6%) patients assigned to placebo (hazard ratio, 0.95; 95% CI, 0.64 to 1.40). The rates of other cardiovascular events were low, with differences between the groups not reaching nominal statistical significance. No safety concerns were identified. CONCLUSIONS: In patients with acute MI as noted above, after approximately 1 year of treatment with dapagliflozin there were significant benefits with regard to improvement in cardiometabolic outcomes but no impact on the composite of cardiovascular death or hospitalization for heart failure compared with placebo. (Funded by AstraZeneca; ClinicalTrial.gov number, NCT04564742.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/evidoa2300286

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 305

Metadata

Authors
James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Eriksson, N., Andersen, K., Austin, D., Arefalk, G., Carrick, D., Hofmann, R., Hoole, S. P., Jones, D. A., Lee, K., Tygesen, H., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Parvaresh Rizi, E., Deanfield, J., & Oldgren, J.
Venue
NEJM Evidence
Published
2024-01-23
Volume
3
Issue
2
Pages
EVIDoa2300286-EVIDoa2300286
ISSN
2766-5526 (ISSN-L)
OpenAlex
W4388592138
Cited by
305
References
31
FWCI
50.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. https://app.cochat.ai/papers/10.1056/evidoa2300286
The paper
James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Eriksson, N., Andersen, K., Austin, D., Arefalk, G., Carrick, D., Hofmann, R., Hoole, S. P., Jones, D. A., Lee, K., Tygesen, H., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Parvaresh Rizi, E., . . . Oldgren, J. (2024). Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evidence. https://doi.org/10.1056/evidoa2300286

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.